IN2012DN02692A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02692A IN2012DN02692A IN2692DEN2012A IN2012DN02692A IN 2012DN02692 A IN2012DN02692 A IN 2012DN02692A IN 2692DEN2012 A IN2692DEN2012 A IN 2692DEN2012A IN 2012DN02692 A IN2012DN02692 A IN 2012DN02692A
- Authority
- IN
- India
- Prior art keywords
- subunit
- immunity against
- inducing immunity
- antigenic peptides
- antibody
- Prior art date
Links
- 230000000890 antigenic effect Effects 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000036039 immunity Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 102000006354 HLA-DR Antigens Human genes 0.000 abstract 1
- 108010058597 HLA-DR Antigens Proteins 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000005585 Poxviridae Infections Diseases 0.000 abstract 1
- 241000700647 Variola virus Species 0.000 abstract 1
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000044166 interleukin-18 binding protein Human genes 0.000 abstract 1
- 108010070145 interleukin-18 binding protein Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25836909P | 2009-11-05 | 2009-11-05 | |
| US25872909P | 2009-11-06 | 2009-11-06 | |
| US12/754,140 US8722047B2 (en) | 2005-03-03 | 2010-04-05 | Humanized anti-HLA-DR antibodies |
| US12/754,740 US8562988B2 (en) | 2005-10-19 | 2010-04-06 | Strategies for improved cancer vaccines |
| US37805910P | 2010-08-30 | 2010-08-30 | |
| PCT/US2010/054668 WO2011056721A2 (en) | 2009-11-05 | 2010-10-29 | Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02692A true IN2012DN02692A (oth) | 2015-09-04 |
Family
ID=43970701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2692DEN2012 IN2012DN02692A (oth) | 2009-11-05 | 2010-10-29 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2496256A4 (oth) |
| CN (1) | CN102573902A (oth) |
| AU (1) | AU2010315432A1 (oth) |
| CA (1) | CA2776563A1 (oth) |
| IN (1) | IN2012DN02692A (oth) |
| WO (1) | WO2011056721A2 (oth) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2014047124A1 (en) * | 2012-09-18 | 2014-03-27 | University Of Washington Through Its Center For Commercialization | Compositions and methods for delivery of antigens to plasmacytoid dendritic cells |
| JP2018508481A (ja) | 2015-02-02 | 2018-03-29 | ザ ユニバーシティ オブ バーミンガム | 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体 |
| EP3377103B2 (en) | 2015-11-19 | 2025-03-12 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| CN109187982B (zh) * | 2018-08-02 | 2021-06-04 | 浙江康佰裕生物科技有限公司 | 一种tlr类疫苗佐剂的筛选和鉴定方法 |
| CN109172818B (zh) * | 2018-08-02 | 2021-10-22 | 浙江康佰裕生物科技有限公司 | 一种蛋白牛痘疫苗及其效力检测方法 |
| KR20210108944A (ko) * | 2018-10-22 | 2021-09-03 | 아이셀킬렉스 테라퓨틱스 엘엘씨 | 돌연변이 백시니아 바이러스 및 이의 용도 |
| CN111474339A (zh) * | 2020-04-17 | 2020-07-31 | 浙江康佰裕生物科技有限公司 | 一种利用荧光标记痘病毒颗粒的方法及其应用 |
| WO2021219619A1 (en) * | 2020-04-27 | 2021-11-04 | Genovie Ab | Methods to generate vaccine compositions that prime human leukocyte antigen class i restricted cd8 t-cell responses against viral non-virion-integral derived epitopes |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194254A (en) * | 1986-05-06 | 1993-03-16 | Connaught Laboratories Limited | Enhancement of antigen immunogenicity |
| WO1994006469A1 (en) * | 1992-09-18 | 1994-03-31 | La Jolla Institute For Allergy And Immunology | Hiv fusion polypeptide |
| ATE395422T1 (de) * | 1995-06-07 | 2008-05-15 | Sanofi Pasteur Ltd | Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems |
| DE69637523D1 (de) * | 1995-06-07 | 2008-06-26 | Sanofi Pasteur Ltd | Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems |
| US6224870B1 (en) * | 1997-01-24 | 2001-05-01 | Genitrix, Ltd. | Vaccine compositions and methods of modulating immune responses |
| US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US7666400B2 (en) * | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US7534866B2 (en) * | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US6958214B2 (en) * | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
| KR101017732B1 (ko) | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | 내재화 항-ｃｄ74 항체 및 그 이용방법 |
| EP1501863A4 (en) * | 2002-05-03 | 2007-01-24 | Sequenom Inc | KINASE ANCHOR PROTEIN, PEPTIDES AND RELATED METHODS THEREOF |
| US7906118B2 (en) * | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| AU2004232928A1 (en) * | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
| BRPI0607486B8 (pt) * | 2005-03-03 | 2021-05-25 | Immunomedics Inc | anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos. |
| AU2006232920B2 (en) * | 2005-04-06 | 2011-09-29 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| AU2006232310B9 (en) * | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| US20090269365A1 (en) * | 2005-04-20 | 2009-10-29 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
| JP5231231B2 (ja) * | 2005-10-19 | 2013-07-10 | アイビーシー・ファーマシューティカルズ・インコーポレーテッド | 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用 |
| CN103242451B (zh) * | 2005-12-16 | 2017-11-21 | Ibc医药公司 | 基于免疫球蛋白的多价生物活性装配体 |
| CA2651285C (en) * | 2006-05-15 | 2014-08-19 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
| CN102119175A (zh) * | 2008-04-10 | 2011-07-06 | Ibc药品公司 | 采用停靠与锁(dnl)技术制备具有增强的药物动力学的四聚细胞因子的模块方法 |
-
2010
- 2010-10-29 IN IN2692DEN2012 patent/IN2012DN02692A/en unknown
- 2010-10-29 WO PCT/US2010/054668 patent/WO2011056721A2/en not_active Ceased
- 2010-10-29 AU AU2010315432A patent/AU2010315432A1/en not_active Abandoned
- 2010-10-29 EP EP10828938.0A patent/EP2496256A4/en not_active Withdrawn
- 2010-10-29 CN CN2010800474188A patent/CN102573902A/zh active Pending
- 2010-10-29 CA CA2776563A patent/CA2776563A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2496256A2 (en) | 2012-09-12 |
| WO2011056721A2 (en) | 2011-05-12 |
| CA2776563A1 (en) | 2011-05-12 |
| WO2011056721A3 (en) | 2011-10-13 |
| AU2010315432A1 (en) | 2012-04-12 |
| EP2496256A4 (en) | 2013-07-17 |
| CN102573902A (zh) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02692A (oth) | ||
| WO2020193688A3 (en) | Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof | |
| MX350274B (es) | Vacunas para hsv-2. | |
| MX2025008006A (es) | Vacunas novedosas del vph16, composiciones y metodos de uso de las mismas | |
| WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
| WO2012034025A3 (en) | Human cytomegalovirus vaccine | |
| MX2018001213A (es) | Nuevos metodos para inducir una respuesta inmunitaria. | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| MD4624B1 (ro) | Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| MX344103B (es) | Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle. | |
| WO2007095320A3 (en) | Hpv antigens, vaccine compositions, and related methods | |
| MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
| EA201892735A1 (ru) | Состав вакцины против hiv | |
| MY170659A (en) | Nucleic acid molecules encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same | |
| WO2007008918A3 (en) | Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof | |
| MX2024004293A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
| NZ601609A (en) | Vaccine vectors and methods of enhancing immune responses | |
| MX389111B (es) | Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso. | |
| EA201071366A1 (ru) | Комбинированная вакцина против кори и вируса папилломы человека | |
| EP3971298A3 (en) | Compositions and methods for inducing an enhanced immune response using poxvirus vectors | |
| WO2016116905A9 (en) | Cmv antigens and uses thereof | |
| MY187896A (en) | Dengue virus vaccine compositions and methods of use thereof | |
| PL1951300T3 (pl) | Zmiana równowagi TH1/TH2 w szczepionkach typu split przeciwko grypie zawierających adjuwant | |
| PH12017501100A1 (en) | Recombinant swinepox virus and vaccines |